Clinical Trial

A Dietary Study for People With Multiple Myeloma

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having participants complete questionnaires. The study will investigate the effects of diet on quality of life, treatment response, and other disease, microbiome, and immune markers.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-07; most recent amendment 2026-05-04.
Trial Details
NCT Number NCT07226609
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Blood Cancer United
Conditions Multiple Myeloma
Enrollment 220 participants
Start Date 2025-11-04
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-05